HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dannis G van Vuurden Selected Research

dipinacoline glutamate

1/2022Neurological Symptom Improvement After Re-Irradiation in Patients With Diffuse Intrinsic Pontine Glioma: A Retrospective Analysis of the SIOP-E-HGG/DIPG Project.
6/2021A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
1/2021Complementary and alternative medicine in children with diffuse intrinsic pontine glioma-A SIOPE DIPG Network and Registry study.
1/2020Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
10/2019Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
11/2018MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
1/2018Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.
11/2017Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.
11/2017A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma.
8/2017External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dannis G van Vuurden Research Topics

Disease

30Diffuse Intrinsic Pontine Glioma
01/2022 - 01/2013
25Neoplasms (Cancer)
01/2021 - 06/2009
13Brain Neoplasms (Brain Tumor)
11/2020 - 12/2011
10Glioma (Gliomas)
11/2020 - 12/2011
4Medulloblastoma
11/2020 - 12/2011
3Glioblastoma (Glioblastoma Multiforme)
11/2020 - 06/2009
2Disease Progression
06/2021 - 10/2019
2Hypothyroidism
12/2018 - 12/2016
2Brain Stem Neoplasms (Brain Stem Tumor)
12/2014 - 01/2014
2Ependymoma
07/2014 - 12/2011
1Ataxia (Dyssynergia)
01/2022
1Weight Gain
10/2021
1Nausea
01/2018
1Precocious Puberty
12/2016
1Hydrocephalus (Hydrocephaly)
12/2016
1Astrocytoma (Pilocytic Astrocytoma)
07/2014
1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)
07/2014
1Neoplasm Metastasis (Metastasis)
09/2012
1Neuroblastoma
11/2005
1Febrile Neutropenia
07/2005
1Hematologic Neoplasms (Hematological Malignancy)
07/2005
1Neutropenia
07/2005

Drug/Important Bio-Agent (IBA)

28dipinacoline glutamateIBA
01/2022 - 01/2013
7Pharmaceutical PreparationsIBA
11/2020 - 01/2013
4Bevacizumab (Avastin)FDA Link
06/2021 - 01/2016
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2021 - 01/2016
3Histones (Histone)IBA
01/2020 - 01/2017
389Zr-bevacizumabIBA
01/2018 - 01/2016
2GemcitabineFDA Link
01/2018 - 11/2017
2Proteins (Proteins, Gene)FDA Link
07/2014 - 08/2012
2Phosphotransferases (Kinase)IBA
02/2013 - 09/2012
1Indicators and Reagents (Reagents)IBA
10/2021
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2021
1Topoisomerase I InhibitorsIBA
06/2021
1Irinotecan (Camptosar)FDA LinkGeneric
06/2021
1Thyroxine (Levothyroxine)FDA LinkGeneric
12/2018
11- (6- (3,5- dichloro- 4- hydroxyphenyl)- 4- ((4- ((dimethylamino)methyl)cyclohexyl)amino)- 1,5- naphthyridin- 3- yl)ethanoneIBA
11/2018
1AnthracyclinesIBA
05/2017
1Doxorubicin (Adriamycin)FDA LinkGeneric
05/2017
11-dodecylpyridoxal (PLD)IBA
05/2017
1liposomal doxorubicin (Doxil)FDA Link
05/2017
1Growth Hormone (Somatotropin)IBA
12/2016
1SteroidsIBA
01/2016
1Ethanol (Ethyl Alcohol)IBA
12/2014
1Carmustine (FIVB)FDA Link
12/2014
1Carrier Proteins (Binding Protein)IBA
07/2014
1multidrug resistance-associated protein 1IBA
01/2013
1LigandsIBA
09/2012
1Ephrin-B1 (Ephrin B1)IBA
09/2012
1EphrinsIBA
09/2012
1ras GTPase-Activating Proteins (ras-GAP)IBA
08/2012
1ras ProteinsIBA
08/2012
1DNA (Deoxyribonucleic Acid)IBA
12/2011
1Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2011
1Cytotoxins (Cytolysins)IBA
12/2011
1olaparibIBA
12/2011
1Poly (ADP-Ribose) Polymerase-1IBA
12/2011
1Glutamic Acid (Glutamate)FDA Link
06/2009
1Glutamate Receptors (Glutamate Receptor)IBA
06/2009
1AMPA Receptors (AMPA Receptor)IBA
06/2009
1alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA
06/2009
1ANNA1 antibodyIBA
11/2005
1Cephalosporins (Cephalosporin Antibiotics)IBA
07/2005
1Cefpirome (HR 810)IBA
07/2005

Therapy/Procedure

8Radiotherapy
06/2021 - 12/2011
5Therapeutics
11/2020 - 07/2014
2Re-Irradiation
01/2022 - 01/2017
2Drug Therapy (Chemotherapy)
11/2020 - 01/2013
2Aftercare (After-Treatment)
11/2019 - 01/2018
1Complementary Therapies (Alternative Medicine)
01/2021
1Terminal Care (Care, Terminal)
04/2016
1Transplantation
01/2014
1Plasma Exchange
11/2005